NI202000023A - Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. - Google Patents
Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.Info
- Publication number
- NI202000023A NI202000023A NI202000023A NI202000023A NI202000023A NI 202000023 A NI202000023 A NI 202000023A NI 202000023 A NI202000023 A NI 202000023A NI 202000023 A NI202000023 A NI 202000023A NI 202000023 A NI202000023 A NI 202000023A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compounds
- monobactamic
- chroman
- treatment
- bacterial infections
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical class O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 abstract 1
- 229960003644 aztreonam Drugs 0.000 abstract 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 monobactam compound Chemical class 0.000 abstract 1
- 239000002132 β-lactam antibiotic Substances 0.000 abstract 1
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566779P | 2017-10-02 | 2017-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202000023A true NI202000023A (es) | 2020-09-24 |
Family
ID=65994576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202000023A NI202000023A (es) | 2017-10-02 | 2020-03-24 | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11433055B2 (enExample) |
| EP (1) | EP3691639B1 (enExample) |
| JP (1) | JP7252948B2 (enExample) |
| KR (1) | KR102425959B1 (enExample) |
| CN (2) | CN111201021B (enExample) |
| AU (1) | AU2018345523B2 (enExample) |
| CA (1) | CA3076022C (enExample) |
| CL (1) | CL2020000860A1 (enExample) |
| CO (1) | CO2020004087A2 (enExample) |
| CR (1) | CR20200148A (enExample) |
| DO (1) | DOP2020000058A (enExample) |
| EA (1) | EA202090604A1 (enExample) |
| ES (1) | ES2968467T3 (enExample) |
| GE (1) | GEP20227406B (enExample) |
| IL (1) | IL273306B (enExample) |
| JO (1) | JOP20200130A1 (enExample) |
| MA (1) | MA50629A (enExample) |
| MX (1) | MX2020003581A (enExample) |
| NI (1) | NI202000023A (enExample) |
| PE (1) | PE20201256A1 (enExample) |
| PH (1) | PH12020550107A1 (enExample) |
| SA (1) | SA520411571B1 (enExample) |
| SG (1) | SG11202002575UA (enExample) |
| UA (1) | UA126000C2 (enExample) |
| WO (1) | WO2019070492A1 (enExample) |
| ZA (1) | ZA202001721B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156697B (zh) * | 2019-05-30 | 2022-05-06 | 常州沃腾化工科技有限公司 | 一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法 |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| SI4175719T1 (sl) | 2020-07-02 | 2025-07-31 | Incyte Corporation | Triciklične sečninske spojine kot zaviralci jak2 v617f |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US20240051931A1 (en) * | 2020-12-03 | 2024-02-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hdac inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
| AU2021473165B2 (en) * | 2021-11-09 | 2025-05-22 | Guangzhou HC New Drug Research Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF |
| US11932637B2 (en) * | 2021-11-18 | 2024-03-19 | Merck Sharp & Dohme Llc | Chromane amidine monobactam compounds for the treatment of bacterial infections |
| JP7671398B2 (ja) * | 2021-11-18 | 2025-05-01 | メルク・シャープ・アンド・ドーム・エルエルシー | クロマンアミジンモノバクタム抗生物質 |
| US12084430B2 (en) | 2022-03-17 | 2024-09-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| EP4558137A2 (en) * | 2022-07-18 | 2025-05-28 | Merck Sharp & Dohme LLC | Chromane amidine monobactam compounds for the treatment of bacterial infections |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
| US5250691A (en) * | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
| CA2783572C (en) | 2005-12-07 | 2016-08-09 | Basilea Pharmaceutica Ag | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
| EP1938822A1 (en) * | 2006-12-21 | 2008-07-02 | Novartis AG | Combination therapy for the treatment of airways disease |
| EA031698B1 (ru) | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Человеческие анти-тау антитела |
| CA2815821C (en) | 2010-11-29 | 2015-07-07 | Pfizer Inc. | Monobactams useful for treating bacterial infections |
| UY34585A (es) | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| MY172458A (en) | 2012-05-31 | 2019-11-26 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| PT3122745T (pt) | 2014-03-24 | 2019-04-30 | Novartis Ag | Compostos orgânicos de monobactama para o tratamento de infeções bacterianas |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| SG10201803472QA (en) | 2014-10-31 | 2018-06-28 | Abbvie Sarl | Substituted chromanes and method of use |
| FR3031423B1 (fr) * | 2015-01-06 | 2018-11-30 | Centre National De La Recherche Scientifique | Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif |
| AU2016371600B2 (en) | 2015-12-15 | 2021-02-18 | Merck Sharp & Dohme Llc | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| JP7034929B2 (ja) * | 2016-03-07 | 2022-03-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 二環式アリールモノバクタム化合物及び細菌感染症を治療するためにそれらを使用する方法 |
-
2018
- 2018-09-27 GE GEAP201815303A patent/GEP20227406B/en unknown
- 2018-09-27 MX MX2020003581A patent/MX2020003581A/es unknown
- 2018-09-27 ES ES18864229T patent/ES2968467T3/es active Active
- 2018-09-27 US US16/651,456 patent/US11433055B2/en active Active
- 2018-09-27 CR CR20200148A patent/CR20200148A/es unknown
- 2018-09-27 AU AU2018345523A patent/AU2018345523B2/en active Active
- 2018-09-27 EP EP18864229.2A patent/EP3691639B1/en active Active
- 2018-09-27 KR KR1020207012234A patent/KR102425959B1/ko active Active
- 2018-09-27 PE PE2020000692A patent/PE20201256A1/es unknown
- 2018-09-27 CA CA3076022A patent/CA3076022C/en active Active
- 2018-09-27 SG SG11202002575UA patent/SG11202002575UA/en unknown
- 2018-09-27 MA MA050629A patent/MA50629A/fr unknown
- 2018-09-27 JO JOP/2020/0130A patent/JOP20200130A1/ar unknown
- 2018-09-27 CN CN201880064269.2A patent/CN111201021B/zh active Active
- 2018-09-27 EA EA202090604A patent/EA202090604A1/ru unknown
- 2018-09-27 JP JP2020518661A patent/JP7252948B2/ja active Active
- 2018-09-27 CN CN202410563311.2A patent/CN118496221A/zh active Pending
- 2018-09-27 UA UAA202002037A patent/UA126000C2/uk unknown
- 2018-09-27 WO PCT/US2018/053039 patent/WO2019070492A1/en not_active Ceased
-
2020
- 2020-03-15 IL IL273306A patent/IL273306B/en unknown
- 2020-03-16 DO DO2020000058A patent/DOP2020000058A/es unknown
- 2020-03-18 ZA ZA2020/01721A patent/ZA202001721B/en unknown
- 2020-03-19 SA SA520411571A patent/SA520411571B1/ar unknown
- 2020-03-20 PH PH12020550107A patent/PH12020550107A1/en unknown
- 2020-03-24 NI NI202000023A patent/NI202000023A/es unknown
- 2020-03-31 CL CL2020000860A patent/CL2020000860A1/es unknown
- 2020-03-31 CO CONC2020/0004087A patent/CO2020004087A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000023A (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. | |
| MX2018005382A (es) | Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| BR112018067930A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
| PH12017502418A1 (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| BR112013032770A2 (pt) | composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase | |
| BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
| MX2015012472A (es) | Derivados de manosa para el tratamiento de infecciones bacterianas. | |
| NZ596628A (en) | Ketolide compounds having antimicrobial activity | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| MX2018001022A (es) | Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos. | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| MX2019001412A (es) | Compuestos de 9-aminometil minociclina y usos de los mismos. | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| CL2024001461A1 (es) | Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas. | |
| AR127695A1 (es) | Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas | |
| CO2024002712A2 (es) | Azálidos inmunomoduladores | |
| TH1701007800A (th) | ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส |